2015 Athersys Phase 2 Ischemic Stroke Clinical Trial Results Dr. David Hess
Your window is the best if you include two additional groups that will get the Mulistem with Tpa & the clot removal in the first 4 hours. The 3rd. group 4-36 hours will get only Multistem.
I estimate that the 3 possibilities will get FDA approval and ATHX will max the market potential for itself.
Volume of 25 M shares traded today, possibly the acquisition started today. It will get the price to $2.5 PPS soon.
Chugai proving that they have timely reaction and they inform the investor about it. ATHX left it investors wounded in the battle field with no concern, they should lose control of this company.
...And you have control of $45M cash on hand. This is zero financial risk with 10,000% up side potential.
Chugai - just buy ATHX in the open market.
$45M cash on hand. Best Stem Cell technology in the market, all for $100M -140M investment cap, probably only $30-40M for control and it is all yours.
$8 - $10B market valuation in 3-5 years.
The ATHX management had the best Stem Cell baby in their hand and they blew it.
The large 19M shares today and 13 M within the last two days is a great opportunity for an hostile TO.
The best we can hope for is Chugai or any other large pharma take over and make this beautiful #1 in the Stem Cell and a $10B operation in 5 years.
Gil, give the keys to the Japanese and keep presenting ATHX. You are doing fine in presentation and you fail in leadership and respecting your investors.
Chugai should make a statement that they are taking control of the new test 6-24 hours and ATHX will be $3 soon after
This will make it a huge success Vs. a failure, with market value of $1B Vs. $80-100M now.
If we still have the MultiStem cell therapy in our body, our chances for recovery is the best available.
Hang on and keep faith that management is still alive and kicking.
Sentiment: Strong Buy